ABBOTT LABORATORIES ABT
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products.
On November 19, 2025, Abbott entered into a definitive agreement to acquire Exact Sciences Corporation (Exact Sciences), which is expected to enable Abbott to enter the cancer diagnostics market. The acquisition is subject to customary closing conditions, including the approval of Exact Sciences shareholders and obtaining the required regulatory clearances.
Abbott has four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $44.33B | $41.95B | $40.11B | $43.65B | $43.08B | $34.61B | $31.90B | $30.58B | $27.39B | $20.85B |
| Cost of revenue | $19.32B | $18.71B | $17.98B | $19.14B | $18.54B | $15.00B | $13.23B | $12.71B | $12.41B | $9.09B |
| Gross profit | $25.01B | $23.24B | $22.13B | $24.51B | $24.54B | $19.61B | $18.67B | $17.87B | $14.98B | $11.76B |
| R&D | $2.94B | $2.84B | $2.74B | $2.89B | $2.74B | $2.42B | $2.44B | $2.30B | $2.26B | — |
| SG&A | $12.33B | $11.70B | $10.95B | $11.25B | $11.32B | $9.70B | $9.77B | $9.74B | $9.18B | $6.74B |
| Total operating expenses | $36.27B | $35.12B | $33.63B | $35.29B | $34.65B | $29.25B | $27.37B | $26.93B | $25.83B | $17.83B |
| Operating income | $8.05B | $6.83B | $6.48B | $8.36B | $8.43B | $5.36B | $4.53B | $3.65B | $1.56B | $3.03B |
| Interest expense | $493.0M | $559.0M | $637.0M | $558.0M | $533.0M | $546.0M | $670.0M | $826.0M | $904.0M | $431.0M |
| Pre-tax income | $8.47B | $7.01B | $6.66B | $8.31B | $8.21B | $4.97B | $4.08B | $2.87B | $2.23B | $1.41B |
| Income tax | $1.94B | $6.39B | $941.0M | $1.37B | $1.14B | $497.0M | $390.0M | $539.0M | $1.88B | $350.0M |
| Net income | $6.52B | $13.40B | $5.72B | $6.93B | $7.07B | $4.50B | $3.69B | $2.37B | $477.0M | $1.40B |
| EPS, basic | 3.73 | 7.67 | 3.28 | 3.94 | 3.97 | 2.52 | 2.07 | 1.34 | 0.27 | 0.94 |
| EPS, diluted | 3.72 | 7.64 | 3.26 | 3.91 | 3.94 | 2.50 | 2.06 | 1.33 | 0.27 | 0.94 |
| Shares, diluted (wtd. avg.) | $1.75B | $1.75B | $1.75B | $1.76B | $1.79B | $1.79B | $1.78B | $1.77B | $1.75B | $1.48B |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.52B | $7.62B | $6.90B | $9.88B | $9.80B | $6.84B | $3.86B | $3.84B | $9.41B | $18.62B |
| Short-term investments | $417.0M | $351.0M | $383.0M | $288.0M | $450.0M | $310.0M | $280.0M | $242.0M | $203.0M | $155.0M |
| Receivables | $7.93B | $6.92B | $6.57B | $6.22B | $6.49B | $6.41B | $5.42B | $5.18B | $5.25B | $3.25B |
| Inventory | $6.49B | $6.19B | $6.57B | $6.17B | $5.16B | $5.01B | $4.32B | $3.80B | $3.60B | $2.43B |
| Total current assets | $26.00B | $23.66B | $22.67B | $25.22B | $24.24B | $20.44B | $15.67B | $14.63B | $20.15B | $26.78B |
| Property, plant and equipment | $11.82B | $10.66B | $10.15B | $9.16B | $8.96B | $9.03B | $8.04B | $7.56B | $7.61B | $5.71B |
| Goodwill | $24.04B | $23.11B | $23.68B | $22.80B | $23.23B | $23.74B | $23.20B | $23.25B | $24.02B | $7.68B |
| Other intangibles | $5.53B | $6.65B | $8.81B | $10.45B | $12.74B | $14.78B | $17.02B | $18.94B | $21.47B | $4.54B |
| Total assets | $86.71B | $81.41B | $73.21B | $74.44B | $75.20B | $72.55B | $67.89B | $67.17B | $76.25B | $52.67B |
| Short-term debt | $3.03B | $1.50B | $1.08B | $2.25B | $0 | $7.0M | $1.28B | $7.0M | $508.0M | $3.0M |
| Total current liabilities | $16.50B | $14.16B | $13.84B | $15.49B | $13.11B | $11.91B | $10.86B | $9.01B | $8.91B | $6.66B |
| Long-term debt | $9.90B | $12.62B | $13.60B | $14.52B | $17.30B | $18.53B | $16.66B | $19.36B | $27.21B | $20.68B |
| Retained earnings | $49.78B | $47.26B | $37.55B | $35.26B | $31.53B | $27.63B | $25.85B | $24.56B | $23.98B | $25.57B |
| Total equity | $52.13B | $47.66B | $38.60B | $36.69B | $35.80B | $32.78B | $31.09B | $30.52B | $30.90B | $20.54B |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $9.57B | $8.56B | $7.26B | $9.58B | $10.53B | $7.90B | $6.14B | $6.30B | $5.57B | $3.20B |
| Depreciation and amortisation | $1.43B | $1.34B | $1.28B | $1.25B | $1.49B | $1.20B | $1.08B | $1.10B | $1.05B | $803.0M |
| Stock-based compensation | $664.0M | $673.0M | $644.0M | $685.0M | $640.0M | $546.0M | $519.0M | $477.0M | $406.0M | $310.0M |
| Capital expenditure | $2.17B | $2.21B | $2.20B | $1.78B | $1.89B | $2.18B | $1.64B | $1.39B | $1.14B | $1.12B |
| Investing cash flow | -$2.42B | -$2.34B | -$3.13B | -$1.74B | -$2.01B | -$2.21B | -$1.81B | -$1.36B | -$9.62B | -$248.0M |
| Financing cash flow | -$6.31B | -$5.40B | -$7.09B | -$7.64B | -$5.49B | -$2.78B | -$4.29B | -$10.39B | -$5.28B | $11.15B |
| Dividends paid | $4.12B | $3.84B | $3.56B | $3.31B | $3.20B | $2.56B | $2.27B | $1.97B | $1.85B | $1.54B |
| Buybacks | $893.0M | $1.29B | $1.23B | $3.79B | $2.30B | $403.0M | $718.0M | $238.0M | $117.0M | $522.0M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001628280-26-010185.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $138.42B | 35.6x | 8.9% |